Milestone Pharmaceuticals (MIST) Competitors $2.08 -0.05 (-2.12%) As of 02:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIST vs. TERN, ANAB, PVLA, MGTX, SIGA, OLMA, KROS, BCAX, KALV, and GOSSShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Terns Pharmaceuticals (TERN), AnaptysBio (ANAB), Palvella Therapeutics (PVLA), MeiraGTx (MGTX), Siga Technologies (SIGA), Olema Pharmaceuticals (OLMA), Keros Therapeutics (KROS), Bicara Therapeutics (BCAX), KalVista Pharmaceuticals (KALV), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Milestone Pharmaceuticals vs. Its Competitors Terns Pharmaceuticals AnaptysBio Palvella Therapeutics MeiraGTx Siga Technologies Olema Pharmaceuticals Keros Therapeutics Bicara Therapeutics KalVista Pharmaceuticals Gossamer Bio Terns Pharmaceuticals (NASDAQ:TERN) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations. Do institutionals & insiders believe in TERN or MIST? 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 1.5% of Terns Pharmaceuticals shares are owned by insiders. Comparatively, 19.5% of Milestone Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is TERN or MIST more profitable? Terns Pharmaceuticals' return on equity of -27.35% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Terns PharmaceuticalsN/A -27.35% -26.18% Milestone Pharmaceuticals N/A -1,672.29%-83.09% Which has preferable valuation and earnings, TERN or MIST? Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTerns PharmaceuticalsN/AN/A-$88.85M-$1.04-7.71Milestone PharmaceuticalsN/AN/A-$41.52M-$0.84-2.47 Which has more volatility and risk, TERN or MIST? Terns Pharmaceuticals has a beta of -0.03, meaning that its stock price is 103% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Do analysts prefer TERN or MIST? Terns Pharmaceuticals presently has a consensus target price of $15.49, indicating a potential upside of 93.24%. Milestone Pharmaceuticals has a consensus target price of $4.50, indicating a potential upside of 116.87%. Given Milestone Pharmaceuticals' higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Terns Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43Milestone Pharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Does the media prefer TERN or MIST? In the previous week, Terns Pharmaceuticals had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 4 mentions for Terns Pharmaceuticals and 2 mentions for Milestone Pharmaceuticals. Milestone Pharmaceuticals' average media sentiment score of 1.34 beat Terns Pharmaceuticals' score of 0.09 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Terns Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Milestone Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMilestone Pharmaceuticals beats Terns Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$176.36M$3.31B$6.11B$10.53BDividend YieldN/A2.29%5.51%4.67%P/E Ratio-2.4721.5485.7226.89Price / SalesN/A414.18580.63183.63Price / CashN/A46.3226.3031.10Price / Book8.3010.0313.236.68Net Income-$41.52M-$52.22M$3.30B$276.44M7 Day Performance3.75%5.50%4.85%3.12%1 Month Performance15.28%11.70%8.50%10.19%1 Year Performance36.51%25.44%87.78%40.24% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals2.4904 of 5 stars$2.08-2.1%$4.50+116.9%+41.3%$176.36MN/A-2.4730News CoveragePositive NewsTERNTerns Pharmaceuticals3.8752 of 5 stars$7.79+2.0%$15.49+98.8%+1.9%$668.58MN/A-7.4940Positive NewsANABAnaptysBio2.5525 of 5 stars$23.27-1.3%$46.13+98.2%-11.0%$660.17M$91.28M-5.19100Gap UpPVLAPalvella Therapeutics2.1024 of 5 stars$62.25+4.5%$67.09+7.8%N/A$659.04M$42.81M-5.14N/AAnalyst ForecastMGTXMeiraGTx3.9236 of 5 stars$8.25+0.9%$24.00+190.9%+102.7%$658.06M$33.28M-4.04300News CoveragePositive NewsGap UpSIGASiga Technologies2.1035 of 5 stars$8.96-2.2%N/A+17.9%$655.91M$138.72M7.9340News CoveragePositive NewsOLMAOlema Pharmaceuticals2.8829 of 5 stars$9.54+0.3%$24.00+151.6%-4.7%$652.71MN/A-4.8270KROSKeros Therapeutics2.1344 of 5 stars$15.95-0.6%$30.00+88.1%-74.4%$651.88M$3.55M51.45100BCAXBicara Therapeutics2.4104 of 5 stars$13.87+18.4%$32.25+132.5%-28.3%$638.93MN/A-4.3832High Trading VolumeKALVKalVista Pharmaceuticals3.79 of 5 stars$12.21-1.5%$26.43+116.5%-3.5%$626.49MN/A-3.10100GOSSGossamer Bio4.1003 of 5 stars$2.82+4.4%$8.50+201.4%+125.2%$613.93M$114.70M-4.55180 Related Companies and Tools Related Companies TERN Alternatives ANAB Alternatives PVLA Alternatives MGTX Alternatives SIGA Alternatives OLMA Alternatives KROS Alternatives BCAX Alternatives KALV Alternatives GOSS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIST) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
